Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Mol Pharm. 2017 Nov 29;15(1):83–96. doi: 10.1021/acs.molpharmaceut.7b00734

Figure 5.

Figure 5.

Pharmacokinetics of 22A peptide (Panel A) and phospholipids (Panel B) after intravenous bolus of various sHDL to Sprague-Dawley rats at 22A peptide dose of 50 mg/kg corresponding to 100 mg/kg dose of phospholipids. Serum peptide concentrations were determined by LC-MS and total choline containing phospholipids was measured by a commercial choline oxidase assay. (*) denotes statistical significant differences of total phospholipids changes for each group compared with sHDL group, with p-values less than 0.0001.